Eupraxia Pharmaceuticals, Inc. (EPRX)
7.02
-0.30
(-4.10%)
USD |
NASDAQ |
Oct 13, 10:19
Eupraxia Pharmaceuticals Enterprise Value : 375.37M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 375.37M |
| October 09, 2026 | 384.54M |
| October 08, 2026 | 391.74M |
| October 07, 2026 | 405.49M |
| October 06, 2026 | 402.87M |
| October 05, 2026 | 403.20M |
| October 02, 2026 | 370.14M |
| October 01, 2026 | 408.77M |
| September 30, 2026 | 491.92M |
| September 29, 2026 | 439.87M |
| September 28, 2026 | 433.65M |
| September 25, 2026 | 420.55M |
| September 24, 2026 | 430.37M |
| September 23, 2026 | 429.06M |
| September 22, 2026 | 457.87M |
| September 21, 2026 | 461.80M |
| September 18, 2026 | 457.87M |
| September 17, 2026 | 444.78M |
| September 16, 2026 | 425.79M |
| September 15, 2026 | 427.10M |
| September 14, 2026 | 424.48M |
| September 11, 2026 | 447.40M |
| September 10, 2026 | 421.21M |
| September 09, 2026 | 425.13M |
| September 08, 2026 | 436.26M |
| Date | Value |
|---|---|
| September 04, 2026 | 446.09M |
| September 03, 2026 | 387.16M |
| September 02, 2026 | 383.88M |
| September 01, 2026 | 311.21M |
| August 31, 2026 | 319.07M |
| August 28, 2026 | 333.14M |
| August 27, 2026 | 377.99M |
| August 26, 2026 | 382.58M |
| August 25, 2026 | 381.92M |
| August 24, 2026 | 372.75M |
| August 21, 2026 | 336.74M |
| August 20, 2026 | 338.71M |
| August 19, 2026 | 355.08M |
| August 18, 2026 | 344.60M |
| August 17, 2026 | 342.64M |
| August 14, 2026 | 336.09M |
| August 13, 2026 | 332.82M |
| August 12, 2026 | 320.38M |
| August 11, 2026 | 334.78M |
| August 10, 2026 | 332.16M |
| August 07, 2026 | 339.36M |
| August 06, 2026 | 332.16M |
| August 05, 2026 | 320.38M |
| August 04, 2026 | 322.99M |
| August 03, 2026 | 322.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 26.40M |
| ProMIS Neurosciences, Inc. | 31.28M |
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
| Oncolytics Biotech, Inc. | 55.32M |
| Sangamo Therapeutics, Inc. | 53.89M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.49M |
| Total Expenses (Quarterly) | 14.49M |
| EPS Diluted (Quarterly) | -0.2278 |
| Earnings Yield | -14.03% |
| Normalized Earnings Yield | -14.03 |